- About Us
- Drug Discovery
- Regenerative Medicine
- News & Events
- Contact Us
Drug Discovery > Neural Diseases
Optimizing Drug Development through the use of pluripotent stem cell-derived human cells
Kadimastem’s unique capabilities enable high throughput screening of lead drug candidates. Our system is capable of screening compounds automatically and quantitatively using a cell-based microscope High Content Screening (HCS) system.
Kadimastem screening platform Highlights:
Kadimastem drug screening system for research use currently includes the followings:
Human oligodendrocytes drug screening assays:
This platform ables access to an exclusive and highly sensitive drug screening system for therapeutic agents against Human demyelinating diseases such as Multiple Sclerosis (MS) and spinal cord traumas. In these demyelinating diseases the therapeutic challenge is how to stimulate sufficient differentiation and remyelination of OPC in order to restore neural functionality, and prevent further deterioration. The current use of rodent OPC for identifying active compounds that stimulates OPC has been shown as unreliable in predicting compound efficacy in humans (Merrill J.E 2009, Neuropsychopharmacology).
Kadimastem Oligodendrocyte drug screening assays enables the company: